317 completed, 51 unknown, 20 terminated, 13 recruiting. 116 Phase 4, 98 Phase 3, 72 Phase 2, 66 Phase 1, 43 Not applicable.
Follow Liraglutide: new trials by email Literature Review of Liraglutide trials Research Report on Liraglutide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Evira Study: Additional Support During Obesity Treatment Digi-physical treatment tool, Evira, Obesity medication with liraglutide or semaglutide - Childhood Obesity, Treatment Adherence | Not applicable | Recruiting | Karolinska Institutet | 40 | 2026-02-13 | 2026-09-10 |
| Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes Incretin-based therapies (GLP-1 and GLP-1/GIP) - Obesity | Enrolling by invitation | Indiana University | 125000 | 2026-01-01 | 2026-06-10 | |
| Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) Liraglutide, Oral Semaglutide, Semaglutide - Obesity | Phase 1 | Recruiting | Novo Nordisk A/S | 71 | 2025-11-07 | 2026-07-21 |
| The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes Liraglutide Pen Injector, Saline Injections - Type 1 Diabetes, Type 2 Diabetes | Phase 2 | Recruiting | Mayo Clinic | 60 | 2025-10-03 | 2026-10-19 |
| A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis 4P004, Placebo (NaCl 0.9%) - Knee Osteoarthritis, Synovitis of Knee | Phase 2 | Active not recruiting | 4Moving Biotech | 129 | 2025-06-17 | 2026-09-21 |
| Liraglutide Treatment in Obese Infertile PCOS Women Liraglutide and metformin, Metformin - PCOS, Obesity | Phase 4 | Recruiting | Peking University Third Hospital | 890 | 2025-05-22 | 2025-05-29 |
| Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY) Liraglutide - Maturity Onset Diabetes of the Young | Phase 2 | Recruiting | Mansa | 50 | 2025-05-08 | 2025-12-17 |
| Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control Metformin, Triple Therapy of Other Oral Antidiabetic Drugs, ganagliflozin - T2DM (Type 2 Diabetes Mellitus) | Phase 4 | Recruiting | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 430 | 2025-03-29 | 2025-11-24 |
| Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists SGLT-2 inhibitor, GLP1-RA - Type 2 Diabetes (T2DM) | Phase 4 | Active not recruiting | MaryAnn Banerji | 60 | 2024-12-21 | 2026-01-08 |
| Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery Liraglutide injection, Placebo injection - Delirium, Postoperative | Phase 3 | Recruiting | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 260 | 2024-11-19 | 2024-12-20 |
| Investigation of the Relationship Between Peripheral and Central Metabolic Changes Induced by GLP-1 Agonists Liraglutide, Placebo - Healthy | Not applicable | Completed | Nils Opel | 10 | 2024-10-21 | 2025-02-10 |
| Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome liraglutide, Metformin - Polycystic Ovary | Phase 3 | Completed | Beni-Suef University | 183 | 2024-08-01 | 2026-08-25 |
| Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy GLP-1 medication - Diabetes Mellitus, Type 2, Obesity | Phase 4 | Completed | The Cleveland Clinic | 69 | 2024-07-31 | 2025-12-05 |
| LIROH - Liraglutide for Obesity in HIV Liraglutide - Obesity, HIV Infections | Phase 4 | Unknown | Brigham and Women's Hospital | 40 | 2024-05-02 | 2024-05-31 |
| Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan. Liraglutide - Obesity | Completed | Novo Nordisk A/S | 300 | 2024-04-08 | 2026-01-09 | |
| Use of Liraglutide in Children Aged 6 to 12 Years With Severe Obesity Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml - Severe Obesity, Cardiovascular Function | Phase 4 | Active not recruiting | University of Sao Paulo General Hospital | 30 | 2024-03-30 | 2026-05-15 |
| Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues Liraglutide Pen Injector [Saxenda], Medication Diary - Multiple Sclerosis, Long COVID | Early Phase 1 | Suspended | University of Chicago | 30 | 2024-01-26 | 2026-03-30 |
| Pharmacological Treatment - An Overview of Its Role in Managing Childhood Obesity Liraglutide 3 mg (Saxenda) - Obesity (Disorder), Child Obesity | Completed | Göteborg University | 128 | 2023-12-20 | 2026-02-27 | |
| Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease Liraglutide, Orlistat - Non-alcoholic Fatty Liver Disease, Obesity | Phase 4 | Unknown | Affiliated Hospital of Nantong University | 102 | 2023-11-01 | 2024-07-15 |
| Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and Infertility Liraglutide + Metformin, Metformin - Polycystic Ovary Syndrome, Obesity | Phase 3 | Unknown | Mỹ Đức Hospital | 188 | 2023-11-01 | 2023-10-23 |
Showing 20 of 427. Sign in to see all of them.
Diabetes Mellitus, Type 2 (199) · Diabetes Mellitus (124) · Obesity (112) · Diabetes Mellitus, Type 1 (36) · Overweight (22) · Nutrition Disorders (18) · Weight Loss (17) · Insulin Resistance (16) · Non-alcoholic Fatty Liver Disease (8) · Cardiovascular Diseases (7) · Inflammation (7) · Polycystic Ovary Syndrome (7) · Metabolic Syndrome (6) · Obesity, Morbid (6) · Glucose Intolerance (5)
Novo Nordisk A/S (123) · University Medical Centre Ljubljana (8) · University at Buffalo (8) · Eli Lilly and Company (7) · Hvidovre University Hospital (5) · Sanofi (5) · Xiangya Hospital of Central South University (5) · Brigham and Women's Hospital (4) · Henrik Gudbergsen (4) · Mayo Clinic (4) · Merck Sharp & Dohme LLC (4) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (4) · University of Miami (4) · AstraZeneca (3) · Canadian Network for Observational Drug Effect Studies, CNODES (3)
United States (138) · Denmark (60) · Germany (54) · United Kingdom (48) · Canada (43) · China (40) · France (32) · Spain (32) · Sweden (28) · Italy (26) · Netherlands (23) · Finland (22) · Belgium (21) · Israel (20) · India (19)
Andrej Janez, MD, PhD (3) · Jing Wu (3) · Pierre Ernst, MD, MSc (3) · Riitta Veijola, MD (3) · Andrej Janez, MD PhD (2) · Eda Vrtacnik Bokal, professor (2) · Henrik R Gudbergsen, MD, PhD (2)
PMID 25504028, PMID 23010561, PMID 39963952, PMID 21450987, PMID 21883806, PMID 22193143, PMID 22862847, PMID 23186975, PMID 19245711, PMID 19491536, PMID 21209033, PMID 22055210, PMID 24561125, PMID 19878259, PMID 28386912, PMID 28950422, PMID 26936426, PMID 27482610, PMID 27817208, PMID 28473337, PMID 26418188, PMID 35797241, PMID 18931095, PMID 19151200, PMID 19491535, PMID 19853906, PMID 19930006, PMID 21883438, PMID 24843595, PMID 25603819, PMID 25896352, PMID 25998481, PMID 26132939, PMID 26225223, PMID 26283739, PMID 26744025, PMID 26833744, PMID 27193270, PMID 27804269, PMID 27871675, PMID 28462892, PMID 28681988, PMID 28854085, PMID 30122305, PMID 31903692, PMID 32267058, PMID 32501595, PMID 33293204, PMID 34463425, PMID 36262060
2014 (14), 2015 (6), 2009 (5), 2008 (4), 2005 (3), 2017 (3), 2016 (2), R56DK067071 (2), UL1TR000135 (2), 1UG3DA050325-01 (1), 2018 (1), K23DK125162 (1), R01DK092653 (1), R01DK125330 (1), U01DK094406 (1)